top of page

Latest News

3.7.25

Virtual twins for personalised CAR T-cell therapy in myeloma

New article highlights CERTAINTY’s approach to advancing personalised treatment

Virtual twins for personalised CAR T-cell therapy in myeloma

15.6.25

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma

PET/CT helps identify high-risk myeloma patients after CAR T therapy

$Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma$

12.6.25

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Registry study confirms cilta-cel’s superior outcomes in real-world multiple myeloma treatment

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

2.5.25

Final episodes of the AI Act video series now available

New videos complete explainer series on EU AI regulation

Final episodes of the AI Act video series now available

30.4.25

Predicting progression events in multiple myeloma from routine blood work

Machine learning model anticipates disease trajectories to support early intervention and personalised care

Predicting progression events in multiple myeloma from routine blood work

bottom of page